Journey Strategic Wealth LLC lifted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 15.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,478 shares of the company's stock after purchasing an additional 468 shares during the quarter. Journey Strategic Wealth LLC's holdings in Eli Lilly and Company were worth $2,872,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. WestEnd Advisors LLC lifted its stake in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Citizens National Bank Trust Department lifted its stake in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $40,000. Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company during the 4th quarter valued at $43,000. Finally, Prudent Man Investment Management Inc. bought a new stake in Eli Lilly and Company during the 4th quarter valued at $48,000. Hedge funds and other institutional investors own 82.53% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the company. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Morgan Stanley restated an "overweight" rating and set a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Finally, HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $1,012.56.
Check Out Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company Price Performance
NYSE LLY traded up $5.85 during trading hours on Thursday, reaching $804.74. The company's stock had a trading volume of 2,784,411 shares, compared to its average volume of 2,826,876. The firm has a market capitalization of $762.69 billion, a price-to-earnings ratio of 65.48, a P/E/G ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The company's 50-day moving average is $770.86 and its two-hundred day moving average is $800.14.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.58 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.75%. Eli Lilly and Company's payout ratio is 48.82%.
About Eli Lilly and Company
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
